191 related articles for article (PubMed ID: 35778553)
1. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
Nicholson HA; Sawers L; Clarke RG; Hiom KJ; Ferguson MJ; Smith G
Br J Cancer; 2022 Oct; 127(7):1340-1351. PubMed ID: 35778553
[TBL] [Abstract][Full Text] [Related]
2. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.
Smith G; Ng MT; Shepherd L; Herrington CS; Gourley C; Ferguson MJ; Wolf CR
Br J Cancer; 2012 Oct; 107(8):1327-36. PubMed ID: 22990650
[TBL] [Abstract][Full Text] [Related]
3. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair.
Serrano MA; Li Z; Dangeti M; Musich PR; Patrick S; Roginskaya M; Cartwright B; Zou Y
Oncogene; 2013 May; 32(19):2452-62. PubMed ID: 22797063
[TBL] [Abstract][Full Text] [Related]
4. Chloroquine reverses chemoresistance via upregulation of p21
Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW
Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
6. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
[TBL] [Abstract][Full Text] [Related]
7. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
[TBL] [Abstract][Full Text] [Related]
8. [Employing DNA Damage Response Inhibitors to Enhance Chemosensitivity of Ovarian Carcinoma Cells].
Cai SY; Tang ZZ; Zeng M; Wang XJ; Lou JY; Liu C; Chen J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 May; 47(3):316-20, 336. PubMed ID: 27468472
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
10. ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity.
Ali R; Alabdullah M; Miligy I; Normatova M; Babaei-Jadidi R; Nateri AS; Rakha EA; Madhusudan S
Cells; 2019 Oct; 8(10):. PubMed ID: 31635307
[TBL] [Abstract][Full Text] [Related]
11. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K
Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278
[TBL] [Abstract][Full Text] [Related]
12. Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
Bélanger F; Fortier E; Dubé M; Lemay JF; Buisson R; Masson JY; Elsherbiny A; Costantino S; Carmona E; Mes-Masson AM; Wurtele H; Drobetsky E
Cancer Res; 2018 Oct; 78(19):5561-5573. PubMed ID: 30072396
[TBL] [Abstract][Full Text] [Related]
13. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
[TBL] [Abstract][Full Text] [Related]
14. DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe.
Ashley AK; Shrivastav M; Nie J; Amerin C; Troksa K; Glanzer JG; Liu S; Opiyo SO; Dimitrova DD; Le P; Sishc B; Bailey SM; Oakley GG; Nickoloff JA
DNA Repair (Amst); 2014 Sep; 21():131-9. PubMed ID: 24819595
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
Sawers L; Ferguson MJ; Ihrig BR; Young HC; Chakravarty P; Wolf CR; Smith G
Br J Cancer; 2014 Sep; 111(6):1150-8. PubMed ID: 25010864
[TBL] [Abstract][Full Text] [Related]
18. Changes in the response of MCF-7 cells to ionizing radiation after the combination of ATM and DNA-PK inhibition.
Ćmielová J; Havelek R; Vávrová J; Řezáčová M
Med Oncol; 2015 May; 32(5):138. PubMed ID: 25801233
[TBL] [Abstract][Full Text] [Related]
19. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
